selegiline has been researched along with oxidopamine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (26.92) | 18.7374 |
| 1990's | 10 (38.46) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YT; Cipriani, PG; Gunsalus, K; Kang, M; Khersonsky, SM; Kyung Kim, Y; Lee, JY; Min, J; Niessen, S; Piano, F; Walsh, DP; Yates, JR | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Gramsbergen, JB; Korf, J; Sebens, JB | 1 |
| Greenshaw, AJ; Juorio, AV; Nguyen, TV | 2 |
| Fozard, JR; Palfreyman, MG; Robin, M; Zreika, M | 2 |
| Knoll, J | 1 |
| Cabbat, FS; Duvoisin, RC; Heikkila, RE; Manzino, L | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Adams, CE; Boyson, SJ; Hoffer, BJ; Hoffman, AF; Hudson, JL | 1 |
| Abercrombie, ED; Wachtel, SR | 1 |
| Ebadi, M; Pfeiffer, RF; Shiraga, H | 1 |
| Blumgart, LH; McCrodden, JM; Shaw, SG; Stuart, ET; Tipton, KF; Wheatley, AM; Zhao, D | 1 |
| Yu, PH; Zuo, D | 1 |
| Haapalinna, A; Heinonen, E; Hervonen, A; Salonen, T; Suhonen, J | 1 |
| Felten, DL; Felten, SY; ThyagaRajan, S | 1 |
| Gentsch, C; Spooren, WP; Waldmeier, P | 1 |
| Chesnut, MD; Dwoskin, LP; Geddes, JW; Jakel, RJ; Maragos, WF | 1 |
| Hengerer, B; Spooren, WP; Waldmeier, PC | 1 |
| Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M | 1 |
| Maruyama, W; Naoi, M | 1 |
| Cano, J; de Pablos, RM; Herrera, AJ; Machado, A; Tomás-Camardiel, M | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
26 other study(ies) available for selegiline and oxidopamine
| Article | Year |
|---|---|
Forward chemical genetic approach identifies new role for GAPDH in insulin signaling.
Topics: Adipocytes; Animals; Caenorhabditis elegans; Cell Line; Cells, Cultured; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Insulin; Molecular Structure; Phosphatidylinositols; Signal Transduction | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
In vivo labelling and axonal transport of monoamine oxidase in the rat basal ganglia using radioactive pargyline.
Topics: Animals; Axonal Transport; Basal Ganglia; Clorgyline; Corpus Striatum; Female; Hydroxydopamines; Kainic Acid; Male; Monoamine Oxidase; Oxidopamine; Pargyline; Premedication; Rats; Rats, Inbred Strains; Selegiline; Substantia Nigra | 1986 |
Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Pargyline; Rats; Rats, Inbred Strains; Selegiline; Substantia Nigra; Tryptamines | 1989 |
Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
Topics: Allylamine; Amines; Animals; Blood Pressure; Brain; Decerebrate State; Dose-Response Relationship, Drug; Drug Synergism; Heart Rate; Hydroxydopamines; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Rats; Rats, Inbred Strains; Selegiline | 1986 |
Depletion of striatal beta-phenylethylamine following dopamine but not 5-HT denervation.
Topics: Animals; Biogenic Amines; Corpus Striatum; Denervation; Dopamine; Hydroxydopamines; Hypothalamus; Male; Oxidopamine; Phenethylamines; Raphe Nuclei; Rats; Rats, Inbred Strains; Selegiline; Serotonin; Substantia Nigra | 1986 |
The pharmacology of (-)deprenyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Aging; Animals; Catecholamines; Corpus Striatum; Dopamine; Humans; Hydroxydopamines; In Vitro Techniques; Monoamine Oxidase; Oxidopamine; Phenethylamines; Pyridines; Selegiline | 1986 |
The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
Topics: Allylamine; Amines; Animals; Body Temperature; Brain; Electric Stimulation; Hemodynamics; Hydroxydopamines; Male; Mice; Monoamine Oxidase Inhibitors; Motor Activity; Norepinephrine; Oxidopamine; Phenethylamines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Spinal Cord; Sympathectomy, Chemical; Sympathetic Nervous System; Tyramine | 1985 |
Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.
Topics: Animals; Clorgyline; Dopamine; Humans; Hydroxydopamines; Isomerism; Levodopa; Male; Oxidopamine; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Stereotyped Behavior; Substantia Nigra | 1981 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Fetal Tissue Transplantation; Levodopa; Male; Mesencephalon; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation; Selegiline; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 1994 |
L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Levodopa; Male; Monoamine Oxidase Inhibitors; Nerve Endings; Oxidopamine; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein.
Topics: Animals; Brain; Dopamine; Drug Combinations; Humans; Male; Metallothionein; Oxidopamine; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Selegiline; Sulfates; Tissue Distribution; Tumor Cells, Cultured; Zinc Compounds; Zinc Sulfate | 1993 |
Effect of orthotopic liver transplantation and chemical denervation of the liver on the activities of hepatic monoamine oxidase and catechol-O-methyltransferase.
Topics: Animals; Catechol O-Methyltransferase; Clorgyline; Isoenzymes; Liver; Liver Transplantation; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Lew; Reference Values; Selegiline; Substrate Specificity; Sympathectomy, Chemical | 1993 |
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Topics: Brain Neoplasms; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Glioma; Humans; Neuroblastoma; Oxidopamine; Selegiline; Tumor Cells, Cultured | 1995 |
Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity.
Topics: Aging; Animals; Immunohistochemistry; Male; Microscopy, Fluorescence; Monoamine Oxidase Inhibitors; Oxidopamine; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Selegiline; Superior Cervical Ganglion; Tyrosine 3-Monooxygenase | 1996 |
Restoration of sympathetic noradrenergic nerve fibers in the spleen by low doses of L-deprenyl treatment in young sympathectomized and old Fischer 344 rats.
Topics: Adrenergic Fibers; Aging; Animals; Immunity, Cellular; Male; Monoamine Oxidase Inhibitors; Nerve Regeneration; Nerve Tissue Proteins; Neuropeptide Y; Norepinephrine; Oxidopamine; Rats; Rats, Inbred F344; Selegiline; Spleen; Sympathectomy, Chemical; Tyrosine 3-Monooxygenase | 1998 |
The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Male; Medial Forebrain Bundle; Oxidopamine; Rats; Rats, Sprague-Dawley; Selegiline | 1999 |
Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
Topics: Animals; Apomorphine; Biological Transport; Clorgyline; Corpus Striatum; Dopamine; Malonates; Medial Forebrain Bundle; Mitochondria; Monoamine Oxidase Inhibitors; Nitro Compounds; Oxidopamine; Propionates; Rats; Selegiline; Substantia Nigra | 1999 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase | 2000 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Future of neuroprotection in Parkinson's disease.
Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamine; Parkinson Disease; Propylamines; Salsoline Alkaloids; Selegiline; Tetrahydroisoquinolines; Tumor Cells, Cultured | 2001 |
Deprenyl enhances the striatal neuronal damage produced by quinolinic acid.
Topics: Animals; Antiparkinson Agents; Biomarkers; Calbindins; Corpus Striatum; Dopamine; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Neurons; Oxidopamine; Parvalbumins; Quinolinic Acid; Rats; Rats, Wistar; Receptors, Dopamine D2; S100 Calcium Binding Protein G; Selegiline; Sympatholytics; Tyrosine 3-Monooxygenase | 2005 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |